Venture debt: the loan instrument for founders who don't need it

Venture debt is having a moment, and the pitch is a seductive one.

Capital without dilution. Additional runway without another six months of investor meetings. To a founder just told the round will take longer and price lower than hoped, it sounds less like a financial instrument than a way out of a problem.

The market appears to agree. 2026 has produced some of the highest UK venture debt loan values since 2023, according to NatWest's analysis of PitchBook data. So the instinct is understandable. If debt is flowing, and debt does not dilute, why is anyone still selling equity?

Here is the question almost nobody asks first. When a lender advances several million pounds to a company with no profits, no hard assets and no certainty of surviving the next few years, what are they holding as security?

Not your technology. Not your revenue.

They are holding your investors.

Venture debt is not an alternative to equity. It is a bet on equity, and on the people already on your cap table writing another cheque. Everything follows from that: who can borrow, what the money can buy, and what happens when things go wrong.

Which is why the same data holds a second figure, far less widely quoted. For every 13 UK venture capital deals this year, roughly one venture debt deal was done.

The money is growing while the number of borrowers stays small. That is not a market opening up. It is a market concentrating around a particular kind of company.

The question is whether you are that kind of company, and the answer has remarkably little to do with how good your business is.


What the lender is actually holding

The British Business Bank's definition is clear: venture debt is lending to early-stage, high-growth companies backed by venture capital. Read that again through a lender's eyes. The venture backing is not a description of the borrower. It is the collateral. Specialist lenders say so more bluntly, underwriting on your investors' credibility rather than your cash flow.

Access turns less on the stage you have reached than on who stands behind you, and whether they hold money in reserve with your name on it.

That distinction does real work. Institutional funds reserve capital to follow their companies through successive rounds, which is exactly why lenders look for them. Angels, for example, do not maintain such reserves. A company carrying £2m of angel money and impressive traction can look less bankable than one that raised less behind a fund with deep reserves and a habit of standing by its companies. A business funded by its founders alone, however well run, is not a candidate on poor terms. It is simply not a candidate.

So the question is not whether you are the right stage. It is whether your lead investor's next cheque would repay this loan, and whether a lender would believe they would write it.


What the UK numbers are really saying

UK venture debt is concentrated in a narrow band of companies, and now you can see why. Venture Growth businesses took 89.5% of loan value and 47.6% of loan volume year to date, per NatWest. Venture Growth is PitchBook's label for its most mature venture stage, well beyond Series B: substantial revenue, an established investor base, often an exit in sight.

The obvious reading is that lenders prefer big companies. The better one is that lenders go where investor reserves are deepest and easiest to verify. At that stage the syndicate is established, follow-on behaviour is documented, and the repayment source can practically be named. At Seed there is nothing to underwrite but hope.

This is also why the Series B squeeze we examined last week bites twice. A thinner Series B market does not simply make equity harder to raise. It weakens the very thing a lender is lending against.

Scale matters too. UK lenders issued 272 venture loans worth £5.3bn in 2025; American lenders issued 943 worth $62.4bn. NatWest's diagnosis is that the difference is familiarity rather than capital. British founders know this instrument less well, so they tend to meet it at the moment they are least equipped to judge it.


The window opens when you least need it

Venture debt is conventionally raised alongside, or shortly after, a completed equity round. Not instead of one. NatWest's figures show the pattern plainly, with close to half of UK Venture Growth companies raising venture capital this year also securing venture debt.

Once the collateral is understood, that timing is obvious. In the month after a round closes, your syndicate's conviction is documented, the valuation is set and the bank balance is at its highest. Your creditworthiness will never be better. Facilities are commonly sized as a proportion of the round just closed, often quoted at 30 to 50% of it, which tells you what is being lent against.

Then the detail that quietly undoes most founder modelling. These are typically three to four year term loans carrying monthly interest and amortisation, per the BVCA. You repay capital during the loan, not at the end. So, the facility adds a fixed monthly outflow to a business with none of the revenue certainty a fixed outflow assumes.

Which produces the inversion at the heart of this instrument. Availability, pricing and covenant flexibility are best when need is lowest, and decay as need rises. The founder investigating venture debt because the round is slipping has begun at the point the answer becomes expensive, or "no". Which is worth knowing years early, because the lenders worth having are those who have watched you hit your numbers for a while. Creditworthiness is a record, not a pitch.


What venture debt can pay for, and what it cannot

Most founders ask what the money can be spent on after deciding they want the loan. It is better asked before, and a distinction needs clearing up first, because two different products travel under the same heading.

Syndicate-backed venture debt, the instrument described so far, is typically secured by an all-assets debenture: fixed charges over specified assets and a floating charge over the business as a whole, intellectual property included. The lender takes security over everything precisely because no single item is worth enough to lend against. That security is a recovery mechanism, not the reason for the loan.

Asset-backed finance is the other door and works the opposite way round. Equipment finance, invoice finance, and facilities like Nscale's £1bn GPU-backed loan, the largest UK venture loan of the past decade, are secured on the asset itself, because somebody else would buy it. Here the lender stops caring about your cap table, which is why this door can be open when the first is shut. If you hold real receivables or standard equipment, ask for this instead. But if your kit is a pilot line built around a customised process, nobody will lend against it.

For syndicate-backed venture debt, use of funds matters, but not as collateral. It matters because the lender is lending against a plan and will use covenants and monthly reporting to track your performance against the one it saw in diligence. And it matters because repayment comes out of cash you do not yet have, whose most likely source is your next round. Spend on a sales expansion where the unit economics are proven and only volume is in question, and that round becomes more likely. Spend in a way that leaves repayment resting on a technical result you have not yet achieved, and the loan is underwritten on an experiment. Lenders see that in diligence, and they price it or decline it.

You cannot pledge the same uncertainty twice.


Who wants this, and why

Which raises a question worth contemplating. Why take venture debt at all, other than to dodge dilution?

There are good answers. An undrawn facility is insurance, so you never negotiate a round from weakness. It closes faster than equity when an opportunity is time-bound. It can carry a company across a milestone that reprices it. One lender describes its best customers unsentimentally: those that raise debt are the ones that could raise equity and choose not to. Which suits the founder who has a choice, rarely the founder most drawn to it.

Your investors may be enthusiastic, often for reasons aligned with yours. Runway to a higher-value milestone serves everyone. It also protects their ownership without consuming reserves, defers a priced round in a market they dislike, and leaves untouched the valuation they carry your company at on their books. Lenders reach companies largely through referrals from investors, not through founders finding them.

So ask who first raised the idea at your board. Then apply the test that matters more than any clause. Is your investor proposing debt alongside their own follow-on cheque, or instead of it? Alongside is conviction. Instead of means they would rather you borrowed someone else's money than risk more of their own, and a lender will reach that conclusion too.


Understanding the downside 

Now the part discussed least, because it only matters when things go wrong.

An equity investor and a lender behave differently in a crisis, and the reason is arithmetic rather than character. A shareholder's upside is unbounded, so funding a recovery can be rational even at poor odds. A lender's return is capped at principal, interest and a small equity warrant. That warrant does pay if the company recovers and eventually exits well, but it is a fraction of what the same recovery delivers to a shareholder, and it arrives years later, while the loss of principal is larger in their terms and closer at hand. The lender's objective is not to save the company. It is to get the money back.

Founders model these as two risks. They are one. Because the loan was underwritten against your syndicate, investor wobble is itself the trigger, and the documents say so. Many venture loans treat the loss of investor support as an event of default, and where that clause is absent a material adverse change provision lets the lender decide for itself that a breach has occurred. Both sources of rescue fail on the same day, for the same reason.

Worse, the debt suppresses the rescue. The lender ranks ahead of everyone, so shareholders weighing fresh money know part of it repays the bank first. And a waiver, where the lender formally agrees not to enforce a covenant you have broken, is not forgiveness. It is a renegotiation entered from a position of weakness, and it is priced: fees, tighter covenants, often a requirement that shareholders inject new equity before the next tranche is released. The remedy compels the dilution the debt was taken to avoid.


What to do with this

If you are considering venture debt, answer these questions first.

Is there an institutional investor on your cap table holding reserves, with a record of using them? If not, the rest is academic. Has a round just closed? That is the window, and if you are asking because the round is slipping, you have already missed it.

Does the spend make your next round more likely, or does it buy time to find out whether the technology works? Only the first is a job for this kind of loan, and if what you need is to finance receivables or equipment, that is a different product and a different conversation. And when it next comes up at your board, ask who raised it, and whether they propose it alongside their own cheque or in place of it.

Because the uncomfortable truth sits underneath all four. The founders who can borrow on good terms are largely the ones who do not need to. That is not a defect in the product. That is the product.

 
Let's talk.